The research department at Highlands Oncology Group in Rogers and Fayetteville was part of a recent clinical trial, leading to a new drug that treats breast cancer. The drug, Kisqali, was developed by Novartis and been approved by the U.S. Food and Drug Administration. It’s the only inhibitor of two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6) in the United States that’s designed for premenopausal women and is an initial therapy with fulvestrant in postmenopausal women.

Highlands Oncology Group

Source: Talk Business

Pin It on Pinterest